Latest California Healthline Stories
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges
Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients’ financial realities are only widening amid the economic crisis of the COVID pandemic.
New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
Promises Kept? On Health Care, Trump’s Claims of ‘Monumental Steps’ Don’t Add Up
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He’s hit some stone walls.
KHN’s ‘What the Health?’: ACA in Peril With Ginsburg’s Seat in Play
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
Election Gift for Florida? Trump Poised to Approve Drug Imports From Canada
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
KHN’s ‘What the Health?’: It’s Scandal Week
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
California Rx: State May Dive Into Generic Drug Market
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.